KR20050059195A - 인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료 - Google Patents

인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료 Download PDF

Info

Publication number
KR20050059195A
KR20050059195A KR1020057005145A KR20057005145A KR20050059195A KR 20050059195 A KR20050059195 A KR 20050059195A KR 1020057005145 A KR1020057005145 A KR 1020057005145A KR 20057005145 A KR20057005145 A KR 20057005145A KR 20050059195 A KR20050059195 A KR 20050059195A
Authority
KR
South Korea
Prior art keywords
ifn
cidp
therapeutic agent
leu
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057005145A
Other languages
English (en)
Korean (ko)
Inventor
알프레드 샌드록
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20050059195A publication Critical patent/KR20050059195A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020057005145A 2002-09-27 2003-09-26 인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료 Ceased KR20050059195A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
US60/414,307 2002-09-27

Publications (1)

Publication Number Publication Date
KR20050059195A true KR20050059195A (ko) 2005-06-17

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005145A Ceased KR20050059195A (ko) 2002-09-27 2003-09-26 인터페론-β를 이용한 만성 염증성 탈수초성다발성신경병증의 치료

Country Status (21)

Country Link
US (2) US20060182715A1 (cg-RX-API-DMAC7.html)
EP (1) EP1575531B9 (cg-RX-API-DMAC7.html)
JP (3) JP2006513990A (cg-RX-API-DMAC7.html)
KR (1) KR20050059195A (cg-RX-API-DMAC7.html)
CN (2) CN102038938A (cg-RX-API-DMAC7.html)
AT (1) ATE520412T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003277006C1 (cg-RX-API-DMAC7.html)
BR (1) BR0314548A (cg-RX-API-DMAC7.html)
CA (1) CA2500189A1 (cg-RX-API-DMAC7.html)
DK (1) DK1575531T3 (cg-RX-API-DMAC7.html)
EA (1) EA009289B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20094699B (cg-RX-API-DMAC7.html)
IS (1) IS7746A (cg-RX-API-DMAC7.html)
MX (1) MXPA05003243A (cg-RX-API-DMAC7.html)
NO (1) NO20052059L (cg-RX-API-DMAC7.html)
NZ (1) NZ565990A (cg-RX-API-DMAC7.html)
PL (1) PL377612A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050255A (cg-RX-API-DMAC7.html)
UA (1) UA86749C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004028472A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502416B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004758A (ko) * 2018-07-04 2020-01-14 서울대학교산학협력단 신경손상의 면역세포치료

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2010117848A1 (en) 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
IN2014CN02982A (cg-RX-API-DMAC7.html) * 2011-10-01 2015-07-03 Glytech Inc
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method
WO2026010306A1 (ko) * 2024-07-02 2026-01-08 주식회사 카인사이언스 탈수초 질환 치료를 위한 펩타이드 및 ivig의 병용 요법
KR20260005781A (ko) * 2024-07-02 2026-01-12 주식회사 카인사이언스 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
WO2000050620A2 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
EP1366075B1 (en) * 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004758A (ko) * 2018-07-04 2020-01-14 서울대학교산학협력단 신경손상의 면역세포치료

Also Published As

Publication number Publication date
AU2003277006B2 (en) 2009-09-10
EA009289B1 (ru) 2007-12-28
IS7746A (is) 2005-03-15
CN1802170A (zh) 2006-07-12
ZA200502416B (en) 2005-10-20
BR0314548A (pt) 2005-08-09
EA200500545A2 (ru) 2005-08-25
RS20050255A (sr) 2007-08-03
GEP20094699B (en) 2009-06-10
JP2006513990A (ja) 2006-04-27
NZ565990A (en) 2009-10-30
NO20052059D0 (no) 2005-04-27
US20120058083A1 (en) 2012-03-08
PL377612A1 (pl) 2006-02-06
NO20052059L (no) 2005-06-27
EP1575531A4 (en) 2008-01-23
CN102038938A (zh) 2011-05-04
WO2004028472A2 (en) 2004-04-08
EP1575531B1 (en) 2011-08-17
JP2011132248A (ja) 2011-07-07
DK1575531T3 (da) 2011-11-21
EA200500545A3 (ru) 2007-04-27
MXPA05003243A (es) 2005-09-12
ATE520412T1 (de) 2011-09-15
WO2004028472A3 (en) 2006-01-19
AU2003277006A1 (en) 2004-04-19
US20060182715A1 (en) 2006-08-17
AU2003277006C1 (en) 2010-04-01
EP1575531B9 (en) 2012-02-22
CA2500189A1 (en) 2004-04-08
JP2007039463A (ja) 2007-02-15
EP1575531A2 (en) 2005-09-21
UA86749C2 (en) 2009-05-25

Similar Documents

Publication Publication Date Title
US20120058083A1 (en) Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta
AU2003256603B2 (en) Therapies for renal failure using interferon-Beta
CN100480266C (zh) 干扰素-β融合蛋白及用途
KR102253597B1 (ko) 듀켄씨 근이영양증의 치료에서의 폴리스타틴
AU2007209722A1 (en) Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP7174149B2 (ja) GLP1-Fc融合タンパク質及びその複合体
JP2006513990A5 (cg-RX-API-DMAC7.html)
KR101216331B1 (ko) 돌연변이된 뉴블라스틴의 중합체 컨주게이트
HRP970654A2 (en) Muteins of obese protein
HK1141998A (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080925

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100827

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110824

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100827

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I